Missouri is currently home to 1892 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
NCT05907629
Recruiting
CAPTIVA-MRI is an observational multimodal MR imaging study that is ancillary to the CAPTIVA trial \[a 3-arm, double-blind Phase III trial conducted at approximately 115 StrokeNet sites randomizing patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.\] The primary goal of this ancillary study is to determine if MRI biomarkers can potentially identify ICAS patients who fail best medical management. The CAPT... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Barnes Jewish Hospital, Saint Louis, Missouri
Conditions: Stroke, Intracranial Atherosclerotic Stenosis (ICAS)
Register for Updates
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
NCT05813327
Recruiting
In this study, patients with soft tissue sarcoma (STS) will receive ADI-PEG 20 and ifosfamide in combination with radiation as neoadjuvant therapy. In phase I of the study, up to 5 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
Register for Updates
APOL1 Genetic Testing in African Americans
NCT05656261
Recruiting
Recent breakthroughs in medical genetics have discovered that a portion of kidney failure affecting the Black community is mediated by coding variants in a gene called apolipoprotein L1 (APOL1) - and that genetic variants, not race - account for increased risk. For APOL1 genetic testing to be applied in a manner that improves patient care and outcomes, more information is needed regarding associations of genotype with clinical parameters related to kidney health. Further, understanding patient p... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/17/2025
Locations: SSM Health Saint Louis University Hospital, Saint Louis, Missouri
Conditions: Genetic Predisposition, Chronic Kidney Diseases, Nephropathy, APOL1 Associated Kidney Disease, Disparities
Register for Updates
Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck
NCT05484115
Recruiting
The HERCULES trial is a Randomized controlled clinical trial designed to prospectively compare endosuture aneurysm repair (ESAR) to standard endovascular aneurysm repair (EVAR) clinical outcomes in treatment of infrarenal abdominal aortic aneurysm (AAA) in subjects having wide proximal aortic neck diameters (≥ 28mm and ≤ 32mm).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: University of Missouri, Columbia, Missouri
Conditions: Aortic Aneurysm, Abdominal
Register for Updates
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
NCT05434598
Recruiting
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Whole Genome Sequencing, Myelodysplastic Syndromes
Register for Updates
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
NCT03900468
Recruiting
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Saint Louis University, Saint Louis, Missouri
Conditions: Epilepsy
Register for Updates
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT00353483
Recruiting
The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Neoplasms
Register for Updates
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061
Recruiting
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Clinical Research Professionals, Chesterfield, Missouri
Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
Register for Updates
Study of BMN 349 Single Dose in (PiZZ) and (PiMZ) Adult Participants
NCT06738017
Recruiting
The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH. Primary outcome measures include incidence of any adverse events (including serious adverse events, dose limit toxicities, and adverse events of special interest), incidence of any laboratory test abnormalities, incidence of lung function test abnormalities and 12-lead ECG parameters. Participants will receive a single dose of either BMN 349 or place... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/14/2025
Locations: Saint Louis University, Saint Louis, Missouri
Conditions: Alpha 1-Antitrypsin Deficiency
Register for Updates
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
NCT06687772
Recruiting
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk. Autologous stem cell transplanta... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/14/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Diffuse Large B Cell Lymphoma
Register for Updates
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
NCT06482437
Recruiting
This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/14/2025
Locations: NextGen Precision Health, Columbia, Missouri
Conditions: Charcot-Marie-Tooth Disease
Register for Updates
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD
NCT06431256
Recruiting
This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Gender:
ALL
Ages:
Between 4 years and 5 years
Trial Updated:
03/14/2025
Locations: HLD200-112 Study Site, Saint Charles, Missouri
Conditions: Attention Deficit Hyperactivity Disorder
Register for Updates